Topics

Sanofi: Dupixent (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal polyposis

08:18 EDT 29 Oct 2019 | FinanzNachrichten

Dupixent (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal polyposis First biologic approved in the European Union for adults with severe chronic rhinosinusiti...

Original Article: Sanofi: Dupixent (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal polyposis

NEXT ARTICLE

More From BioPortfolio on "Sanofi: Dupixent (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal polyposis"

Quick Search